REGENXBIO Inc. (RGNX)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, REGENXBIO Inc. reported revenue of $170.44M, up 104.5% from the prior year. The company ran a net loss, with a net margin of -113.8%. It held $453.03M in total assets against $350.30M in total liabilities.
Key ratios (FY2025)
-94.6%
Operating margin
-113.8%
Net margin
-188.7%
Return on equity
+104.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M | $154.57M | $35.23M | $218.50M | $10.39M | $4.59M |
| Cost of Revenue | — | $33.57M | $37.21M | $54.55M | $51.83M | $35.71M | $8.24M | $9.64M | $1.71M | — |
| Operating Income | -$161.20M | -$233.35M | -$268.13M | -$262.88M | $159.98M | -$119.23M | -$149.00M | $88.10M | -$75.89M | -$65.34M |
| Net Income | -$193.88M | -$227.10M | -$263.49M | -$280.32M | $127.84M | -$111.25M | -$94.73M | $99.94M | -$73.17M | -$62.97M |
| EPS (Diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| Total Assets | $453.03M | $465.99M | $573.97M | $833.27M | $1.11B | $708.16M | $497.91M | $543.81M | $198.68M | $172.73M |
| Total Liabilities | $350.30M | $206.34M | $262.23M | $317.07M | $349.61M | $330.41M | $47.71M | $34.97M | $15.65M | $10.99M |
| Shareholders' Equity | $102.73M | $259.65M | $311.74M | $516.20M | $764.30M | $377.75M | $450.20M | $508.85M | $183.03M | $161.74M |
| Cash & Equivalents | $34.47M | $57.53M | $34.52M | $96.95M | $345.21M | $338.43M | $69.51M | $75.56M | $46.66M | $24.84M |
| Operating Cash Flow | -$123.96M | -$173.12M | -$218.41M | -$207.49M | $218.88M | -$54.06M | -$107.70M | $104.65M | -$57.99M | -$48.56M |
| Capital Expenditures | $2.41M | $2.44M | $9.96M | $30.72M | $84.17M | $26.87M | $11.72M | $13.28M | $7.16M | $8.15M |
| Shares Outstanding | 50.89M | 49.55M | 44.05M | 43.30M | 42.83M | 37.48M | 36.99M | 36.12M | 31.30M | 26.48M |